Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

325767

Sigma-Aldrich

Lanthanum(III) carbonate hydrate

99.9% trace metals basis

Synonym(s):

Fosrenol, Lanthanum(3+) tricarbonate hydrate

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Linear Formula:
La2(CO3)3·xH2O
CAS Number:
54451-24-0
Molecular Weight:
457.84 (anhydrous basis)
EC Number:
209-599-5
MDL number:
MFCD00149757
UNSPSC Code:
12352302
PubChem Substance ID:
24859532
NACRES:
NA.23

Assay

99.9% trace metals basis

form

powder

composition

Degree of hydration, 2-5

reaction suitability

reagent type: catalyst
core: lanthanum

impurities

≤1500.0 ppm Trace Rare Earth Analysis

SMILES string

O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O

InChI

1S/3CH2O3.2La.H2O/c3*2-1(3)4;;;/h3*(H2,2,3,4);;;1H2/q;;;2*+3;/p-6

InChI key

AFCUGQOTNCVYSW-UHFFFAOYSA-H

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

nwg

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCK6773
MKCJ1347
MKCG2307
MKCF9267
MKCC3328

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Reiko Inoue et al.
Clinical and experimental nephrology, 23(6), 859-864 (2019-03-02)
This study aims to describe the regional variance in prescriptions for chronic kidney disease (CKD) medications and to analyze regional characteristics to identify the sources of these differences by utilizing the National Database of Health Insurance Claims, which provides more
Stefan P Schumacher et al.
Nephrology (Carlton, Vic.), 24(2), 221-226 (2018-02-27)
Hyperphosphataemia is associated with increased mortality and morbidity in end stage renal disease. Despite phosphate binder therapy, a large proportion of patients do not reach the treatment target. In five contemporary binders we explored the influence of pH and phosphate
Atsushi Yaguchi et al.
PloS one, 12(7), e0180430-e0180430 (2017-07-14)
The effects of PA21, a novel iron-based and non-calcium-based phosphate binder, on hyperphosphatemia and its accompanying bone abnormality in chronic kidney disease-mineral and bone disorder (CKD-MBD) were evaluated. Rats with adenine-induced chronic renal failure (CRF) were prepared by feeding them
Olivier Phan et al.
BioMed research international, 2015, 515606-515606 (2015-07-30)
Elevated serum phosphorus, calcium, and fibroblast growth factor 23 (FGF23) levels are associated with cardiovascular disease in chronic renal disease. This study evaluated the effects of sucroferric oxyhydroxide (PA21), a new iron-based phosphate binder, versus lanthanum carbonate (La) and sevelamer

Articles

Thermoelectric Performance of Perovskite-type Oxide Materials

The prevailing strategies for heat and electric-power production that rely on fossil and fission fuels are having a negative impact on the environment and on our living conditions.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service